R Royalty Pharma
$48.57
| Market Cap | $28.09B |
| P/E Ratio | 27.29 |
| Forward P/E | 8.92 |
| Dividend Yield | 1.94% |
| Beta | 0.39 |
| 52W Range | $30.13 - $48.57 |
| # Hedge Funds | 3 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 3 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Pat Dorsey Dorsey Asset Management | 7.59% | $87.31M | 2,259,469 | Reduce 3.87% |
| Samantha McLemore Patient Capital Management | 4.97% | $128.81M | 3,333,675 | Add 6.92% |
| Torray Funds Torray Investment Partners | 4.12% | $28.76M | 744,355 | Add 5.90% |
Insider Trading
| Insider Name of the company insider who made the trade 84 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Coyne Terrance P.EVP & CFO | Sale | 32,916 | $48.33 | $1.59M | 01 Apr 2026 | 01 Apr 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 1,875 | $48.33 | $90.62K | 01 Apr 2026 | 01 Apr 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 1,875 | $45.53 | $85.37K | 23 Mar 2026 | 23 Mar 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 32,916 | $45.53 | $1.50M | 23 Mar 2026 | 23 Mar 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 583 | $47.01 | $27.41K | 02 Mar 2026 | 04 Mar 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 10,429 | $47.01 | $490.31K | 02 Mar 2026 | 04 Mar 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 1,292 | $46.67 | $60.30K | 02 Mar 2026 | 04 Mar 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 22,487 | $46.67 | $1.05M | 02 Mar 2026 | 04 Mar 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 1,875 | $45.32 | $84.97K | 23 Feb 2026 | 25 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 32,916 | $45.32 | $1.49M | 23 Feb 2026 | 25 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 1,875 | $45.32 | $84.97K | 23 Feb 2026 | 25 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 32,916 | $45.32 | $1.49M | 23 Feb 2026 | 25 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 1,087 | $43.29 | $47.06K | 04 Feb 2026 | 04 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 19,076 | $43.29 | $825.85K | 04 Feb 2026 | 04 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 19,076 | $43.29 | $825.85K | 04 Feb 2026 | 04 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 1,087 | $43.29 | $47.06K | 04 Feb 2026 | 04 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 6,195 | $42.84 | $265.41K | 03 Feb 2026 | 04 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 108,759 | $42.84 | $4.66M | 03 Feb 2026 | 04 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 108,759 | $42.84 | $4.66M | 03 Feb 2026 | 04 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 6,195 | $42.84 | $265.41K | 03 Feb 2026 | 04 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 5,843 | $42.08 | $245.90K | 02 Feb 2026 | 04 Feb 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 102,581 | $42.08 | $4.32M | 02 Feb 2026 | 04 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 5,843 | $42.08 | $245.90K | 02 Feb 2026 | 04 Feb 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 102,581 | $42.08 | $4.32M | 02 Feb 2026 | 04 Feb 2026 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $41.09 | $821.81K | 30 Jan 2026 | 02 Feb 2026 |
| Marshall UristEVP, Research & Investments | Sale | 20,000 | $41.09 | $821.81K | 30 Jan 2026 | 02 Feb 2026 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $40.26 | $805.11K | 23 Jan 2026 | 26 Jan 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 3,750 | $39.35 | $147.56K | 20 Jan 2026 | 23 Jan 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 65,832 | $39.35 | $2.59M | 20 Jan 2026 | 23 Jan 2026 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $39.52 | $790.35K | 16 Jan 2026 | 20 Jan 2026 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $40.78 | $815.63K | 09 Jan 2026 | 13 Jan 2026 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $38.48 | $769.65K | 02 Jan 2026 | 06 Jan 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 65,832 | $38.42 | $2.53M | 02 Jan 2026 | 06 Jan 2026 |
| Coyne Terrance P.EVP & CFO | Sale | 3,750 | $38.42 | $144.06K | 02 Jan 2026 | 06 Jan 2026 |
| Marshall UristEVP, Research & Investments | Sale | 20,000 | $38.48 | $769.65K | 02 Jan 2026 | 06 Jan 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 3,750 | $38.42 | $144.06K | 02 Jan 2026 | 06 Jan 2026 |
| Terrance P. CoyneEVP & CFO | Sale | 65,832 | $38.42 | $2.53M | 02 Jan 2026 | 06 Jan 2026 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $39.32 | $786.38K | 26 Dec 2025 | 29 Dec 2025 |
| Marshall UristEVP, Research & Investments | Sale | 20,000 | $39.32 | $786.38K | 26 Dec 2025 | 29 Dec 2025 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $38.38 | $767.58K | 19 Dec 2025 | 22 Dec 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 30,654 | $38.50 | $1.18M | 18 Dec 2025 | 19 Dec 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 79,346 | $38.57 | $3.06M | 17 Dec 2025 | 19 Dec 2025 |
| Urist MarshallEVP, Research & Investments | Sale | 20,000 | $38.32 | $766.42K | 16 Dec 2025 | 17 Dec 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 65,832 | $38.36 | $2.53M | 15 Dec 2025 | 17 Dec 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 3,750 | $38.36 | $143.85K | 15 Dec 2025 | 17 Dec 2025 |
| Urist MarshallEVP, Research & Investments | Sale | 18,242 | $39.15 | $714.22K | 05 Dec 2025 | 09 Dec 2025 |
| Urist MarshallEVP, Research & Investments | Sale | 23,334 | $39.15 | $913.59K | 05 Dec 2025 | 09 Dec 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 110,000 | $39.77 | $4.38M | 03 Dec 2025 | 05 Dec 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 3,750 | $39.87 | $149.50K | 01 Dec 2025 | 03 Dec 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 65,832 | $39.87 | $2.62M | 01 Dec 2025 | 03 Dec 2025 |
| Urist MarshallEVP, Research & Investments | Sale | 18,242 | $39.90 | $727.86K | 01 Dec 2025 | 03 Dec 2025 |
| Urist MarshallEVP, Research & Investments | Sale | 23,333 | $39.93 | $931.63K | 01 Dec 2025 | 03 Dec 2025 |
| Marshall UristEVP, Research & Investments | Sale | 18,242 | $39.90 | $727.86K | 01 Dec 2025 | 03 Dec 2025 |
| Marshall UristEVP, Research & Investments | Sale | 23,333 | $39.93 | $931.63K | 01 Dec 2025 | 03 Dec 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 65,832 | $39.87 | $2.62M | 01 Dec 2025 | 03 Dec 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 3,750 | $39.87 | $149.50K | 01 Dec 2025 | 03 Dec 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 624 | $37.96 | $23.69K | 24 Nov 2025 | 26 Nov 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 10,686 | $37.96 | $405.64K | 24 Nov 2025 | 26 Nov 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 55,146 | $38.67 | $2.13M | 24 Nov 2025 | 26 Nov 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 3,126 | $38.67 | $120.88K | 24 Nov 2025 | 26 Nov 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 55,146 | $38.67 | $2.13M | 24 Nov 2025 | 26 Nov 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 624 | $37.96 | $23.69K | 24 Nov 2025 | 26 Nov 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 3,126 | $38.67 | $120.88K | 24 Nov 2025 | 26 Nov 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 10,686 | $37.96 | $405.64K | 24 Nov 2025 | 26 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 230 | $39.03 | $8.98K | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 2,770 | $38.29 | $106.05K | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 25,530 | $38.28 | $977.26K | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 4,599 | $39.01 | $179.39K | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 47,401 | $38.28 | $1.81M | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 2,470 | $39.01 | $96.35K | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 4,628 | $39.01 | $180.53K | 19 Nov 2025 | 21 Nov 2025 |
| Lloyd George W.EVP, Investments & CLO | Sale | 47,798 | $38.28 | $1.83M | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 4,599 | $39.01 | $179.39K | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 47,401 | $38.28 | $1.81M | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 230 | $39.03 | $8.98K | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 2,770 | $38.29 | $106.05K | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 2,470 | $39.01 | $96.35K | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 25,530 | $38.28 | $977.26K | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 4,628 | $39.01 | $180.53K | 19 Nov 2025 | 21 Nov 2025 |
| George W. LloydEVP, Investments & CLO | Sale | 47,798 | $38.28 | $1.83M | 19 Nov 2025 | 21 Nov 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 65,844 | $39.30 | $2.59M | 17 Nov 2025 | 19 Nov 2025 |
| Coyne Terrance P.EVP & CFO | Sale | 3,750 | $39.30 | $147.39K | 17 Nov 2025 | 19 Nov 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 3,750 | $39.30 | $147.39K | 17 Nov 2025 | 19 Nov 2025 |
| Terrance P. CoyneEVP & CFO | Sale | 65,844 | $39.30 | $2.59M | 17 Nov 2025 | 19 Nov 2025 |
Frequently Asked Questions
What is RPRX stock price today?
Royalty Pharma (RPRX) is currently trading at $48.57. The stock has a 52-week range of $30.13 to $48.57 and a market capitalization of $28.09B.
Is RPRX a good stock to buy in 2026?
Royalty Pharma has a P/E ratio of 27.3 (forward P/E: 8.9), a dividend yield of 1.94%, and 1-year performance of +56.4%. 3 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling RPRX stock?
There have been 84 insider transactions for RPRX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has RPRX stock performed over the past year?
Royalty Pharma (RPRX) has returned +56.4% over the past 12 months. The stock traded between $30.13 and $48.57 during this period, and is currently at $48.57.
Which hedge funds own RPRX (Royalty Pharma)?
3 tracked hedge funds currently hold RPRX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is RPRX's market cap and valuation?
Royalty Pharma (RPRX) has a market capitalization of $28.09B. The trailing P/E ratio is 27.3 and forward P/E is 8.9. The stock is classified in the Healthcare sector.
What is RPRX's revenue and profitability?
Royalty Pharma reported revenue of $2.38B with net income of $770.95M and a profit margin of 0.32%. The stock has a beta of 0.39.
What sector is RPRX in and who are its biggest institutional holders?
Royalty Pharma (RPRX) operates in the Healthcare sector. It is held by 3 tracked hedge funds. See the ownership table above for the complete list.